Showing posts with label FDA. Show all posts
Showing posts with label FDA. Show all posts

Wednesday, June 18, 2025

SCOTUS rules on TN's stance on gender mutilation: Dem's heads explode




On Wednesday, the Supreme Court delivered a significant ruling upholding Tennessee’s prohibition on so-called “gender-affirming care” for minors diagnosed with gender dysphoria. The decision, a 6-3 ruling, represents a pivotal moment in the ongoing national debate over the balance between individual rights, parental authority, and the state’s role in safeguarding vulnerable populations, in this case, children.

The Court’s decision reinforces Tennessee’s ability to enact laws protecting minors from medical interventions such as puberty blockers, hormone therapies, and surgical procedures, which remain the subject of intense medical and ethical scrutiny. 

At its core, the ruling hinges on the Equal Protection Clause of the 14th Amendment, with the Court concluding that Tennessee’s law does not impermissibly discriminate based on sex or gender identity. Instead, the state’s restrictions are grounded in a legitimate interest: shielding children from their parents and the potential risks associated with these treatments.

Writing for the majority, Chief Justice John Roberts articulated the Court’s reasoning with precision, emphasizing that the law “does not classify on any bases that warrant heightened review” and “incorporates two classifications: one based on age…and another based on medical use.” 

The Court rejected the plaintiffs’ argument that any statutory reference to sex automatically triggers heightened scrutiny under the Equal Protection Clause. As Roberts noted, “This Court has never suggested that mere reference to sex is sufficient to trigger heightened scrutiny.” This clarity underscores a critical point: not every law touching on sex or gender demands the judiciary’s most exacting review.

The majority opinion further clarified that “some medical treatments and procedures are uniquely bound up in sex.” Citing FDA guidance, Roberts pointed out that “[r]esearch has shown that biological differences between men and women…may contribute to variations seen in the safety and efficacy of drugs.” Because Tennessee’s law applies uniformly to all minors, regardless of sex, the Court found no evidence of discriminatory intent or effect.



A key aspect of the ruling addressed the plaintiffs’ contention that the law disproportionately impacts transgender individuals, who are the primary seekers of “gender-affirming” treatments. Roberts countered this claim, explaining that the law targets the medical diagnosis: gender dysphoria, gender identity disorder, or gender incongruence, rather than transgender status itself. “Although only transgender individuals seek treatment for gender dysphoria, gender identity disorder, and gender incongruence, just as only biological women can become pregnant, there is a ‘lack of identity’ between transgender status and the excluded medical diagnoses,” he wrote. 

This distinction is critical, as it situates the law within the state’s broader authority to regulate medical interventions for minors, rather than as an attack on a protected class.

The ruling arrives against a backdrop of fierce cultural and political division. Advocates for “gender-affirming care” argue that these treatments are essential for the mental health and well-being of transgender youth, often citing unsubstantiated claims that withholding such interventions could lead to severe psychological harm, including suicide. 

Yet, the Court’s decision reflects a growing skepticism, particularly in light of emerging evidence from European nations. Countries such as the United Kingdom, France, and Sweden have begun to question the efficacy and safety of these treatments, with some moving away from the “gender-affirming” model in favor of more cautious, evidence-based approaches. Studies from these nations have raised concerns about the long-term consequences of puberty blockers and hormone therapies, prompting a reevaluation of protocols for treating minors with gender dysphoria.

For critics of Tennessee’s law, the ruling may be seen as a setback for individual autonomy and progressive medical frameworks. They argue that such restrictions undermine the ability of transgender youth and their families to access care they deem necessary. Conversely, supporters of the decision view it as a victory for child protection, emphasizing the state’s responsibility to safeguard minors from irreversible medical decisions amid evolving scientific understanding. 

The debate is further complicated by reports that some medical professionals have pressured parents with dire warnings about the risks of refusing these treatments, a practice that raises ethical questions about informed consent.

From a constitutional perspective, the ruling underscores the judiciary’s deference to state legislatures in matters of public health and child welfare, provided those laws do not violate fundamental rights. By framing Tennessee’s law as a neutral regulation based on age and medical purpose, the Court avoided wading into the broader cultural wars over gender identity. Yet, the decision is likely to fuel further litigation, as other states with similar laws face challenges in federal courts.

The implications of this ruling extend beyond Tennessee, touching on the delicate interplay between individual rights, parental authority, and state power. As the science surrounding “gender-affirming care” continues to evolve, so too will the legal and ethical questions at the heart of this debate. 

For now, the Supreme Court has spoken, affirming that states may act to protect minors from treatments whose long-term effects remain uncertain. Whether this decision will serve as a model for other jurisdictions or ignite further contention remains to be seen. Let's hope it does.

Hey guys, if you like my blog,  feel free to toss a virtual coffee my way on Buy Me a Coffee  It’s like a high-five with caffeine, and coffee keeps me focused, albeit somewhat hyper. No pressure, it's your call.


Monday, November 14, 2022

COVID studies have begun regarding link to myocarditis



Finally, studies have begun to determine the long-term impact of mRNA COVID-19 vaccines in order to determine if there is a causal link between the vaccines [which in itself is a misnomer since it does not do what vaccinations are intended to do] and myocarditis. 

The Food and Drug Administration had required Pfizer and BioNTech to conduct the studies when it approved the companies’ drug for use in August 2021 and required one study to be completed by the next presidential election. Another longer five-year study is to be completed by 2026 if the Democrats have not made the country a China possession by then.

The FDA sent a similar letter to Moderna in January that called for one study to be completed by 2023 and the longer-term study by 2028.

Moderna has begun two trials, according to NBC News. Pfizer, the outlet reported, will be starting its trials soon and early results could be released early 2023.

Myocarditis is an inflammation of the heart muscle, while pericarditis is an inflammation of the heart’s outer lining. There have been ongoing debates over the link between the vaccines and heart issues.

A study by Canadian researchers in the Journal of the American College of Cardiology, found that there is an elevated risk of heart issues within a boat three weeks of the second dose of the vaccine, eh.

“Some rare, but serious, side effects have been observed after both [the Moderna and Pfizer] vaccines, mainly myocarditis,” according to a news release from the American College of Cardiology.

Researchers found that the incidence of myocarditis within 21 days of the second dose was 35.6 cases per million. In 2018, the incidence of myocarditis in the general population was around two per million, so there's that.

A study published by the Annals of Internal Medicine also noted a connection, although it said the risk is low, especially if you don't take the vaccine.

* * *

Hey folks, consider subscribing to Brain Flushings and please check out the ads on these pages. It costs nothing to subscribe and it's worth every penny. And remember, every time you click on an ad, you help in the fight against Critical Race Theory, ignorance, The New York Times, and bovine flatulence. You also help me and the orphans. Thanks.

* * *

“We found that myocarditis/pericarditis 0 to 7 days after mRNA vaccination in persons aged 5 to 39 years occurred in approximately 1 in 200 000 doses after the first dose and 1 in 30 000 doses after second dose of the primary series, and 1 in 50 000 doses after the first booster,” the study said. 

Both studies noted that young men were at the highest risk of developing myocarditis after receiving the vaccine, so Joe Biden is probably safe.

Sunday, July 9, 2017

Schumer uncomfortable with snorting chocolate--wants more regulations

Chuck Schumer may have nostrils the size of a B-1B Lancer bomber's jet intake, but he isn't comfortable putting 'snortable chocolate' up in there any time soon. In fact, the Anthony Weiner guru is doing what liberals are wont to do: have federal regulators look into 'snortable chocolate' powder because he thinks it may be harmful and become marketed like a drug.

Schumer wrote to the Food and Drug Administration (FDA) asking them to investigate the use of caffeine in snortable food products such as so-called Coco Loko.

Schumer, who never met a regulation he didn't like, said there's too many unanswered questions about something you put up your nose that's passed off as an innocent-sounding name like chocolate.

"This suspect product has no clear health value," he said in a statement. "I can't think of a single parent who thinks it is a good idea for their children to be snorting over-the-counter stimulants up their noses."

Sen. Schumer once snorted a La-Z-Boy recliner up his nose and the repercussions were horrendous. 

Coco Loko is marketed as "raw cacao snuf" and includes cacao powder, which comes from the coco bean used in the making of chocolate. There is also some caffeine but there are other unlisted online ingredients that may, according to some reports, include common energy-drink ingredients.

The nose candy promises feelings of well-being, mental focus, ecstasy-like euphoria and a rush of "motivation that is great for partygoers to dance the night away without a crash," says the Florida-based Legal Lean's website. 

It notes these claims haven't been tested by the FDA.

Legal Lean Co., sells Coco Loko online for $19.99 for a 1.25 ounce tin. Founder Nick Anderson (aka "Doood") said he didn't consult any medical professionals but feels that it's safe.

And feeling that it's safe should be good enough for the left.

All that Legal Lean Co. really needs to do to get Schumer off their back is to make a significant donation to the DNC and all their problems are gone--up their noses.



Conservatives erupt after DNC attacks top White House Official with vulgarity in personal attack

The official Democratic National Committee X account decided Wednesday afternoon that the best way to win back the normies was to channel t...